Detailed Narrative
Q1 FY27 Financial Performance Overview
Anlon Healthcare Limited reported a robust Q1 FY27, with total income reaching ₹87.62 crores, a significant 163.03% increase year-on-year from ₹33.31 crores in Q1 FY26. EBITDA for the quarter stood at ₹15.65 crores, up 150% YoY from ₹6.26 crores in the prior year. Profit after tax also saw substantial growth, rising 133.24% YoY to ₹8.28 crores from ₹3.55 crores in Q1 FY26, demonstrating strong top-line and bottom-line expansion.
EBITDA Margin Moderation and Recovery Outlook
Despite strong revenue growth, the company's EBITDA margin moderated to approximately 17% in Q1 FY27. This was primarily attributed to a sharp increase in raw material prices due to global geopolitical situations, which temporarily impacted the cost structure. Additionally, the consolidation of operating expenses from the newly acquired Remember India Health links, currently in an investment and turnaround phase, also weighed on margins. Management expects EBITDA margins to gradually recover and stabilize in the 25% to 30% range during Q2 and Q3 of FY27, driven by initiated price revisions and operational efficiencies.
Strategic Transformation through Acquisitions
Q1 FY27 was a transformational quarter for Anlon, marked by the completion of the acquisition of a 63.98% stake in Remember India Health links on May 8, 2026. This strategic move provides access to over 30 formulation dossiers and signifies Anlon's entry into finished dosage formulation, evolving it into a more integrated pharmaceutical company. Existing subsidiaries, Apiqo Organics and Bizotic Lifesciences, further strengthen backward integration and manufacturing capabilities, contributing to an expanded installed capacity of 1400-1600 metric tons per annum.
FY27 and FY28 Revenue and Profitability Guidance
The company maintains its FY27 revenue guidance of ₹350-400 crores, with a more ambitious target of ₹700 crores for FY28, contingent on timely capacity expansion. For FY27, Apiqo is projected to contribute ₹120-150 crores, standalone Anlon ₹180 crores, and Bizotic ₹60 crores to total revenue. Consolidated EBITDA margins are expected to be 25-27% for FY27, with PAT margins projected at 12-13% for both FY27 and FY28, reflecting confidence in sustained profitability.
Capacity Expansion and Funding Strategy
Anlon is undertaking a new CAPEX of approximately ₹130 crores for its standalone facility, which will add 1200 metric tons of manufacturing capacity, bringing the total to 1600 metric tons. This significant expansion is expected to be commissioned by Q1 FY28, subject to statutory approvals. The funding for this CAPEX will be a mix of ₹70 crores from new debt, with an estimated interest rate of 8.5-8.6%, and the remaining portion financed through internal accruals, indicating a balanced funding approach.
Product Pipeline and Regulatory Filings Progress
The company is actively advancing its product pipeline, with plans to file seven new DMFs (Drug Master Files) within FY27, demonstrating ongoing R&D efforts. Progress is also being made on CDMO projects, with commercial supply expected for one molecule by Q3 FY27 and two additional molecules by Q4 FY27 or Q1 FY28. New subsidiaries, Anlon Biologics (for peptides/biosimilars) and Anlon Medicare (for surgical implants), are projected to commence revenue generation by Q4 FY28 and Q2 FY28, respectively, diversifying future income streams.